David Grayzel is a Partner at Atlas Venture, where he focuses on creating and investing in novel therapeutics companies. An alumnus of Harvard Medical School and Stanford University, he has co-founded multiple biotech startups, including Q32 Bio and Vedere Bio, leveraging his extensive experience in clinical development and business operations.
With deep roots in the Boston area from his medical training at Harvard, residency at Mass General, and his entire venture career, David is embedded in the local community. This long-standing connection suggests a likely affinity for local culture and sports.
He served as the founding CEO of Q32 Bio, a company focused on autoimmune and inflammatory diseases which he co-founded at Atlas.
David Grayzel
Partner at Atlas Venture
Cambridge, Massachusetts, United States
Overview
Topics They Care About
Biotech Venture Creation
He specializes in co-founding and building new biotech companies, often serving in initial leadership roles to guide their strategy and growth.
Novel Therapeutics
His investment focus is on companies developing innovative new drugs across various modalities, including gene editing and protein therapeutics.
Autoimmune Diseases
He co-founded and was the founding CEO of Q32 Bio, a clinical-stage company specifically targeting autoimmune and inflammatory diseases.
Media Appearances
Atlas Venture Names Life Sciences Investor David Grayzel Partner. Featured in Wall Street Journal
Work History
Partner at Atlas Venture
6-2010
Managing Director at Atlas Venture Development Corp.
8-2002 - 6-2010
VP Clinical Development and Medical Affairs at Infinity Pharmaceuticals
Director Corporate Development and Business Operations at Dyax Corp
Intern, Resident at Massachusetts General Hospital
Education
1992 - 1997
MD from Harvard Medical School
BA from Stanford University
More Information
Social Presence :
Prographics :
Exp : 23
Location : Cambridge, Massachusetts, United States
Job Level : Mid-senior
Designation : Partner at Atlas Venture
